NICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients - GuruFocus.com

Value Investing | Market insights and news of the investment gurus. Value investing screens and valuation tools.

• Idefirix® becomes the first and only product recommended by NICE for the desensitization of highly sensitized patients waiting for a kidney transplant1
• NICE considers Idefirix® to be … [+9623 chars]
  full article...